B2B Vault: The Biz To Biz Podcast

There are genuine operational insights buried here - the RUO label/marketing mismatch rule, the 30-day update requirement, the affiliate compliance standard, and the nuance that LegitScript certification is not an automatic processor approval - but they are heavily diluted by host tangents, self-promotion, and repetitive affirmations. The ratio of signal to filler is low.

“if a website is labeling a product as research use only on the bottle, but the entire page is talking about fat loss or recovery or anti aging or longevity, any of these hot topics. Right. The label and the marketing are telling two different stories and frankly, the marketing is going to win that one.”

“we do ask for certified entities to update us within 30 days of that change on the website”

The episode is almost entirely compliance 101 for a narrow merchant audience with no contrarian or first-principles thinking. Analogies like the driver's license comparison are worn, and the regulatory landscape described is simply restated from public FDA guidance rather than offering any novel synthesis.

“It's sort of like um, sort of like a driver's license really. Like we're essentially providing this licensure with, via the certification to prove that you're qualified to be on the road, but you still have to follow the rules of the road.”

“compliance shouldn't be an aftersight, it shouldn't be a, uh. Well, we're up and ready. We're ready to open our doors but we've forgotten a few things”

Angela Salter is VP at the actual certification body under discussion - she is a genuine operational practitioner with direct subject-matter authority, not a generic thought leader. Her knowledge of the GLP-1 compounding enforcement window and the affiliate compliance standard is credible and specific, though the interview does not fully exploit her depth.

“we reached out to merchants that we knew were selling GLP1s under that compounding, um, sort of open window that was then allowed. We reached out and we verified, hey, what's your plan for business to cease those by these time frames”

“we take a look at who is your, who is your pharmacy that you are contracted with? Who is your compounding pharmacy? Who are your affiliated partners”

The episode has pockets of real specificity - the 14,000 websites Eli Lilly reported, fine ranges of $50K - $2M+, a cited $70M settlement, the 30-day update rule, and named compounds like BPC-157 and TB-500 - but much of the conversation consists of vague anecdotes and unverifiable personal claims from the host, pulling the overall score down.

“They reported 14,000 websites to the authorities, federal authorities, to Visa, MasterCard. 14,000.”

“fined anywhere from 50 grand, 200 grand. I know a couple people who were fined into the millions”

The host is knowledgeable about payments but routinely answers his own questions, delivers extended personal anecdotes that displace guest insight, and never challenges Angela on a single claim. The guest's comment 'What do you need me here for, Alan?' captures the dynamic accurately.

“What do you need me here for, Alan?”

“And I can answer some of these questions, some of that.”